In a nutshell This study aimed to investigate the outcomes for acute myeloid leukemia (AML) patients treated with venetoclax (Venclexta) and azacitidine (Vidaza) who achieved complete remission (CR) and minimal measurable residual disease (MRD) after treatment. This study concluded that patients who achieved both CR and minimal...
Read More
In a nutshell This study examined the association between long-term use of three different tyrosine kinase inhibitors (TKIs) and the occurrence of vascular (blood vessel) adverse events (side effects; VAEs) in patients with chronic myeloid leukemia (CML). The data showed a possibly higher risk of developing VAEs when patients with CML were...
Read More
In a nutshell This study aimed to investigate long-term treatment-free remission (TFR) for patients with chronic-phase (CP) chronic myeloid leukemia (CML) who were treated with nilotinib (Tasigna) as a second-line treatment. This study concluded that TFR is safe and durable in these patients. Some background The...
Read More
In a nutshell This study provided an updated 5-year assessment of treatment-free remission (TFR) after frontline nilotinib (Tasigna) treatment in patients with chronic-phase (CP) chronic myeloid leukemia (CML). The data showed sustained, long-term high TFR rates with effectiveness and safety in these patients. Some background Long-term treatments...
Read More
In a nutshell This study aimed to investigate if allogeneic stem cell transplantation (allo-SCT) was a safe and effective option for the treatment of patients with chronic lymphocytic leukemia (CLL) after treatment with novel agents (NA). This study concluded that this treatment option was safe and effective for patients with...
Read More
In a nutshell This study aimed to investigate fatigue (tiredness) as a side effect of tyrosine kinase treatment in patients with chronic myeloid leukemia and its relationship to physical activity. This study concluded that identifying patients at risk of severe fatigue and working to reduce fatigue during treatment of...
Read More
In a nutshell This study aimed to investigate the occurrence of atrial fibrillation (abnormal heart rhythm) in patients with chronic lymphocytic leukemia who are treated with ibrutinib. This study concluded that atrial fibrillation does not require ibrutinib treatment to be stopped but is associated with worse outcomes for...
Read More
In a nutshell The study evaluated the occurrence of differentiation syndrome (DS) in patients with IDH-mutated acute myeloid leukemia (AML) under ivosidenib (Tibsovo) and enasidenib (Idhifa) therapy. The authors found that DS is a common and adverse condition in such patients. Some background Mutations or changes in the isocitrate dehydrogenase (IDH)...
Read More
In a nutshell This study aimed to investigate kidney function in patients with chronic-phase (CP) chronic myeloid leukemia (CML) before and after tyrosine kinase inhibitor (TKI) treatment. This study concluded that long-term TKI treatment leads to kidney side effects in these patients that may be irreversible after stopping...
Read MoreIn a nutshell This study aimed to investigate second-line tyrosine kinase inhibitor (TKI) treatment in patients with chronic-phase chronic myeloid leukemia (CP-CML) who had failed first-line TKI treatment. This study concluded that these patients have good outcomes with second-line TKI treatment. Some background Tyrosine kinase...
Read More
In a nutshell This study aimed to evaluate glucose (blood sugar) and lipid (fat) metabolism between dasatinib, nilotinib, and imatinib in patients with chronic-phase chronic myeloid leukemia. This study concluded that dasatinib and nilotinib had a negative impact on glucose and lipid...
Read MoreIn a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells. The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH,...
Read More
